XNASHCWB
Market cap15mUSD
Dec 26, Last price
0.42USD
1D
5.03%
1Q
-18.25%
IPO
-91.88%
Name
HCW Biologics Inc
Chart & Performance
P/E
—
P/S
5.56
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
3m
-57.72%
Net income
-25m
L+69.77%
CFO
-23m
L+116.77%
Profile
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 2,842 -57.72% | 6,722 | |||
Cost of revenue | 23,042 | 21,801 | 13,693 | ||
Unusual Expense (Income) | |||||
NOPBT | (20,200) | (15,079) | (13,693) | ||
NOPBT Margin | |||||
Operating Taxes | (178) | (505) | |||
Tax Rate | |||||
NOPAT | (20,200) | (14,901) | (13,188) | ||
Net income | (24,994) 69.77% | (14,723) 19.14% | (12,357) 113.80% | ||
Dividends | (2,822) | ||||
Dividend yield | 3.40% | ||||
Proceeds from repurchase of equity | 24 | 16 | 56,030 | ||
BB yield | -0.05% | -0.02% | -67.52% | ||
| Debt | |||||
Debt current | (1,800) | ||||
Long-term debt | 6,333 | 6,424 | |||
Deferred revenue | |||||
Other long-term liabilities | 14 | ||||
Net debt | 1,138 | (27,238) | (50,036) | ||
| Cash flow | |||||
Cash from operating activities | (22,514) | (10,386) | (10,976) | ||
CAPEX | (6,203) | (10,275) | (47) | ||
Cash from investing activities | 3,797 | 14,708 | (35,019) | ||
Cash from financing activities | (15) | 6,273 | 49,269 | ||
FCF | (27,506) | (24,586) | (9,432) | ||
| Balance | |||||
Cash | 3,595 | 32,062 | 36,714 | ||
Long term investments | 1,600 | 1,600 | 11,522 | ||
Excess cash | 5,053 | 33,326 | 48,236 | ||
Stockholders' equity | (70,529) | (45,534) | (30,634) | ||
Invested Capital | 90,295 | 89,387 | 80,027 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 35,929 | 35,822 | 35,768 | ||
Price | 1.23 -36.02% | 1.91 -17.47% | 2.32 | ||
Market cap | 44,014 -35.83% | 68,592 -17.34% | 82,982 | ||
EV | 45,152 | 41,355 | 86,461 | ||
EBITDA | (19,065) | (14,361) | (13,149) | ||
EV/EBITDA | |||||
Interest | 283 | 127 | |||
Interest/NOPBT | |||||